Coyne Terrance P. 4

What Happened

• Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), reported open-market sales on April 1, 2026. He disposed of 1,875 shares for $90,622 and 32,916 shares for $1,590,890, for a total of 34,791 shares and roughly $1,681,512 in proceeds. These sales were reported as dispositions (code S).

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 2, 2026 (timely under Form 4 rules).
• Reported price: weighted average $48.33 per share; actual trade prices ranged from $48.07 to $48.67.
• Total shares sold: 34,791; total proceeds: approximately $1,681,512.
• Shares owned after transaction: not specified on the Form 4 for direct holdings. Remarks disclose indirect/exchangeable interests: RPI US Partners 2019, LP exchangeable into 6,448,180 Class A shares and Class E shares of RPH exchangeable into 1,807,277 Class A shares (Class E shares are subject to vesting).
• Footnotes: (F1) All transactions were effected pursuant to a 10b5-1 trading plan adopted August 8, 2025. (F2) Reported price is a weighted average; the filer will provide breakdown on request.

Context

• These were pre-arranged sales under a 10b5-1 plan, which typically indicate pre-scheduled transactions rather than ad-hoc market-timing. Sales reduce the insider’s position but, by themselves, do not necessarily signal management’s view of company prospects.